The Technical Analyst
Select Language :
Rigel Pharmaceuticals Inc [RIGL]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Rigel Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Rigel Pharmaceuticals Inc is listed at the  Exchange

-0.67% $1.480

America/New_York / 28 mar 2024 @ 16:00


Rigel Pharmaceuticals Inc: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 259.56 mill
EPS: -0.140
P/E: -10.57
Earnings Date: Apr 29, 2024
SharesOutstanding: 175.38 mill
Avg Daily Volume: 1.107 mill
RATING 2024-03-28
B+
Neutral
RATINGS
Rating CashFlow: Buy
Return On Equity: Neutral
Return On Asset: Buy
DE: Strong Sell
P/E: Strong Buy
Price To Book: Strong Sell
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -10.57 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.80x
Company: PE -10.57 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 1.368 - 1.592

( +/- 7.57%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-02-28 Schorno Dean L Buy 78 500 Employee Stock Option (right to buy)
2024-02-28 Schorno Dean L Buy 62 500 Employee Stock Option (right to buy)
2024-02-28 Santos David A Buy 80 000 Employee Stock Option (right to buy)
2024-02-28 Santos David A Buy 78 500 Employee Stock Option (right to buy)
2024-02-28 Rodriguez Raul R Buy 300 000 Employee Stock Option (right to buy)
INSIDER POWER
92.88
Last 99 transactions
Buy: 9 521 500 | Sell: 304 047

Forecast: 16:00 - $1.470

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $1.470
Forecast 2: 16:00 - $1.470
Forecast 3: 16:00 - $1.470
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.480 (-0.67% )
Volume 0.782 mill
Avg. Vol. 1.107 mill
% of Avg. Vol 70.67 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Rigel Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Rigel Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Rigel Pharmaceuticals Inc

Last 10 Buy & Sell Signals For RIGL

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$1.125N/AActive
Profile picture for
            Rigel Pharmaceuticals Inc

RIGL

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Last 10 Buy Signals

Date Signal @
USDDUSDMar 29 - 06:480.997
ETHWUSDMar 29 - 06:484.35
GRTUSDMar 29 - 06:45$0.398
KCSUSDMar 29 - 06:44$11.84
GTUSDMar 29 - 06:43$9.65
WNXMUSDMar 29 - 06:3872.57
ALPHUSDMar 29 - 06:362.72
LEASHUSDMar 29 - 06:34572.59
FLIPUSDMar 29 - 06:345.05
XMONUSDMar 29 - 06:29911.39

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.